Acadia Healthcare Company, Inc. Quarterly Report Released - Here’s What You Should Know

Acadia Healthcare Company, Inc.
Quarter Ended June 30, 2025

Key Financial Metrics

• Revenue for Q2 2025 was $869.2 million (up 9.2% from $796.0 million in Q2 2024). For the six months ended June 30, 2025, revenue was $1,639.7 million (up 4.8% from $1,564.1 million in the prior-year period).
• Net income attributable to Acadia for Q2 2025 was $30.1 million ($0.33 per diluted share), compared to $78.5 million ($0.85 per diluted share) in Q2 2024. For the six months ended June 30, 2025, net income attributable to Acadia was $38.5 million ($0.42 per diluted share), down from $154.9 million ($1.68 per diluted share) in the prior-year period.
• Cash and cash equivalents were $131.4 million as of June 30, 2025, up from $76.3 million at year-end 2024.
• Adjusted EBITDA (as presented for internal management purposes in the filing) was not specifically provided, but the operational results focus on revenue growth and expense control.
• Long-term debt stood at $2,247.0 million as of June 30, 2025 (up from $1,880.1 million at December 31, 2024), following a refinancing and issuance of $550.0 million of 7.375% Senior Notes due 2033, and the funding of a new $650.0 million Term Loan Facility.
• Cash provided by operations for the six months ended June 30, 2025 was $145.0 million (versus $(150.1) million in the prior-year period).
• Share repurchases totaled 132,073 shares in Q2 2025 at an average price of $30.20 per share. The buyback program authorizes up to $300 million of annual repurchases, with $250 million remaining as of June 30, 2025.
• Total assets as of June 30, 2025 were $6,308.4 million; total equity was $3,078.0 million.

Key Results and Trends

• Same facility revenue grew 9.5% for the quarter and 5.8% year-to-date, driven by a 1.8% increase in patient days and 7.5% growth in revenue per patient day.
• Medicaid accounted for the majority of revenue (59.5% in Q2 2025), followed by commercial payors (24.0%), Medicare (13.7%), self-pay (1.5%), and other (1.3%).
• Salaries, wages, and benefits remained the largest expense at 52.0% of revenue in Q2 2025.
• Transaction, legal, and other costs for the quarter were $64.4 million (vs. $6.1 million for Q2 2024), primarily due to $53.5 million in costs related to government investigations.
• Depreciation and amortization expense for Q2 was $49.0 million.
• The Company recorded an $8.7 million gain on sale of a facility during the quarter and a $1.5 million non-cash property impairment charge.
• Net cash used in investing activities for the six months was $334.0 million (mainly for capital expenditures and acquisitions).
• As of June 30, 2025, the Company had $828.3 million availability under its revolving credit facility.

Risks

• Legal and Regulatory: The company faces significant ongoing legal and regulatory risks, with $84.5 million in government investigations-related costs year-to-date 2025 (compared to $2.5 million in the prior year). There are ongoing lawsuits including Desert Hills litigation, securities class actions, and derivative actions where ultimate liabilities cannot be reasonably estimated.
• Reimbursement: Revenue is highly exposed to state and federal funding, especially Medicaid (59.5% of revenue). Legislative changes such as those from the One Big Beautiful Bill Act (OBBBA), which changes Medicaid mechanisms beginning in 2028, could materially impact future revenue.
• Debt/Interest Rates: Substantial leverage after new debt issuances increases sensitivity to interest rate risks and increases debt service obligations. Interest expense grew to $35.1 million in Q2 2025 (from $29.2 million in Q2 2024).
• Labor: The business remains vulnerable to labor shortages, higher turnover, and competition for clinical staff with SWB expense at 52.0% of revenue.
• Operational: Risks include the integration of acquisitions, cybersecurity threats, natural disasters, and the ability to expand facilities under restrictive state policies.
• Litigation/Settlements: Active legal settlements and government investigations remain a risk, with $3.5 million settlement expense recognized in 2025 and $95.5 million in “transaction, legal and other costs.”
• Patient Incidents and Reputation: Negative media coverage or regulatory scrutiny on patient care outcomes could adversely impact results.

Management Discussion and Outlook

• Management emphasizes Acadia’s position as the leading publicly traded provider of behavioral healthcare in the U.S. and sees continuing demand for behavioral health services.
• Key growth drivers include increased same facility revenue (9.5% in Q2), longer average length of stay, and improving revenue per patient day.
• The company faces margin pressures due to elevated SWB expense and heightened legal/government investigation costs, which have meaningfully reduced net income year-over-year despite revenue growth.
• Major cost increases relate to litigation and government investigations, which reached $64.4 million in Q2 and drove down quarterly profit margins (net margin at 3.5% versus 9.9% in Q2 2024).
• Capital investment remains strong with over $334 million in cash used for acquisitions and facility expansions in the first half of 2025.
• Liquidity has improved with a rise in cash on hand and access to a new $1.0 billion credit facility, although balance sheet leverage has also increased.
• Management notes possible future impacts from changes in federal or state healthcare policy (specifically Medicaid), as well as continuing inflationary and interest rate pressures.

Investor Takeaway

Acadia delivered strong topline growth in Q2 and year-to-date 2025 but saw a sharp drop in net income, driven mainly by high legal/government investigation costs and growing interest expense following its refinancing activities. While same-facility growth and cash generation remain solid and liquidity is strong, investors should weigh the substantial and potentially ongoing legal/regulatory risks, greater leverage, and exposure to further Medicaid funding changes. The company is reinvesting in operations and continuing share repurchases, indicating confidence in future prospects but also suggesting ongoing volatility in margins and net earnings in the near-term.

Visit Publicview AI to search and analyze millions of SEC filings using AI.